Financial Performance
2022 was a year in which we set all-time highs in several
financial categories - including Revenue and Adjusted Diluted EPS.
Financial Performance
Three-year summary for the years ended December 31
Millions, Except Per Share Data | % Change | ||||
|---|---|---|---|---|---|
| 2022 | 2021 | 2020 | 22/21 | 21/20 | |
Revenues | $100,330 | $81,288 | $41,651 | 23 | 95 |
Reported net income (1) | $31,372 | $21,979 | $9,159 | 43 | * |
Reported diluted EPS (1) | $5.47 | $3.85 | $1.63 | 42 | * |
Adjusted income (2) | $37,717 | $23,196 | $12,601 | 63 | 84 |
Adjusted diluted EPS (2) | $6.58 | $4.06 | $2.24 | 62 | 82 |
Net cash provided by operating activities | $29,267 | $32,580 | $14,403 | (10) | * |
Cash dividends paid | $8,983 | $8,729 | $8,440 | 3 | 3 |
- Reported net income is defined as Net income attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.
- Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP Net income attributable to Pfizer Inc. common shareholders and reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2022 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable U.S. GAAP measures and additional information.
Detailed information on our financial and operational performance can be found in our 2022 Annual Report on Form 10-K.
Top 10 Medicines and Vaccines
Take a look at our breakdown of the top medicines and vaccines by revenue from 2022.
Select an option below
- $37,806 million
COMIRNATY® 1 - $18,933 million
PAXLOVID®
(nirmatrelvir tablets and ritonavir tablets) - $6,480 million
ELIQUIS® (apixaban) 2 - $6,337 million
PREVNAR® Family 3 - $5,120 million
IBRANCE® (palbociclib) - $2,447 million
VYNDAQEL® Family 4 - $1,796 million
XELJANZ® (tofacitinib) - $1,198 million
XTANDI® (enzalutamide) 5 - $1,003 million
ENBREL® (etanercept) - $1,003 million
INLYTA® (axitinib)
- COMIRNATY refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the COMIRNATY Original/Omicron BA.1 Vaccine, and COMIRNATY Original/Omicron BA.4/BA.5 Vaccine. COMIRNATY includes direct sales and alliance revenues related to sales of the above-mentioned vaccines.
- ELIQUIS includes alliance revenues and direct sales.
- PREVNAR Family includes revenues from PREVNAR 13/PREVENAR 13 (pediatric and adult) and PREVNAR 20/APEXXNAR (adult).
- VYNDAQEL Family includes global revenues from VYNDAQEL, as well as revenues for VYNDAMAX in the U.S. and VYNMAC in Japan.
- XTANDI represents alliance revenues.